Top

Published in:

01-09-2010 | Invited Review

A review of malignant meningiomas: diagnosis, characteristics, and treatment

Authors: Simon Hanft, Peter Canoll, Jeffrey N. Bruce

Published in: Journal of Neuro-Oncology | Issue 3/2010

Abstract

Anaplastic or malignant meningiomas (WHO Grade III) represent the most rare but aggressive subtype, accounting for 1–3% of all intracranial meningiomas. Due in large part to their scarcity, malignant meningiomas have been understudied and therefore represent an area where significant clinical advances may be made. To this point, our understanding of the genetic and histologic attributes of these lesions has grown, though the management and treatment of these aggressive tumors is less well elucidated and thus has room for further study. In this review, we describe the current understanding of malignant meningiomas in terms of their genetic alterations and unique histologic markers. Using this as a foundation, we will then discuss the current therapeutic strategies for managing these lesions and the future direction that such interventions may take.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon

Cushing HW, Eisenhardt LC (1938) Serial enumeration of meningiomas. In: Thomas CC (ed) Meningiomas their classification regional behavior, life history and surgical end results. Springfield, Thomas CC, pp 56–73

Perry A, Louis DN, Scheithauer BW, Budka H, Von Deimling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 164–172

Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamardies M, Menei P, Deruty R, Moreau JJ, Fevre-Montange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367–375CrossRefPubMed

Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, Weber DC, Baumert BG, Canyilmaz E, Yalman D, Szutowicz E, Tzuk-Shina T, Mirimanoff RO (2008) Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients a multicenter, retrospective study of the rare cancer network. Int J Radiat Oncol Biol Phys 71:1388–1393PubMed

Zulch K (1979) Histological typing of central nervous system tumours. World Health Organization, Geneva, pp 53–55

Commins D, Atkinson RD, Burnett M (2007) Review of meningioma histopathology. Neurosurg Focus 23(4):1–9 E3CrossRef

Gladin CR, Salsano E, Menghi F, Grisoli M, Ghielmetti F, Milanesi I, Pollo B, Brock S, Cusin A, Finocchiaro G, Bruzzone MG (2007) Loss of heterozygosity studies in extracranial metastatic meningiomas. J Neurooncol 85(1):81–85CrossRefPubMed

Rajaram V, Brat D, Perry A (2004) Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol 35(11):1413–1418CrossRefPubMed

10.

Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046–2056PubMed

11.

Jaaskelainen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25(3):233–242CrossRefPubMed

12.

Gianni C, Rushing EJ, Hainfellner JA (2007) Hemangiopericytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 178–180

13.

Ribalta T, McCutcheon IE, Aldape K, Bruner J, Fuller GN (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28(11):1532–1536CrossRefPubMed

14.

Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120CrossRefPubMed

15.

Ozen O, Demirhan B, Altinors N (2005) Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol 24(5):219–224PubMed

16.

Modha A, Gutin PH (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57(3):538–550CrossRefPubMed

17.

Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA, Knosp E (2004) Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 27(4):238–245CrossRefPubMed

18.

Hsu C, Pai C, Kao H, Hsueh C, Hsu W, Lo C (2010) Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci 17(5):584–587CrossRefPubMed

19.

Hakyemez B, Yildirim N, Gokalp G, Erdogan C, Parlak M (2006) The contribution of diffusion-weighted MR imaging to distinguishing typical from atypical meningiomas. Neuroradiology 48:513–520CrossRefPubMed

20.

Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, Lim CCT (2008) Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol 29(6):1147–1152CrossRefPubMed

21.

Shiino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T (1999) Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg 91:928–934CrossRef

22.

Demir MK, Iplikcioglu AC, Dincer A, Arslan M, Sav A (2006) Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 60(1):48–55CrossRefPubMed

23.

Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, Takano S, Matsumura A (2008) New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol 18:2901–2911CrossRefPubMed

24.

Toh C-H, Castillo M, Wong AM-C, Wei K-C, Wong H-F, Ng S-H, Wan Y-L (2008) Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR Am J Neuroradiol 29(9):1630–1635CrossRefPubMed

25.

Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, Patro S, Saini J, George U, Sarma PS (2010) Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol (Epub ahead of print)

26.

Riemenschneider M, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054CrossRefPubMed

27.

Leone PE, Bello MJ, de Campos JM et al (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231–2239CrossRefPubMed

28.

Ozaki S, Nishizaki T, Ito H, Sasaki K (1999) Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol 41:167–174CrossRefPubMed

29.

Bostrom J, Meyer-Puttlitz B, Wolter M et al (2001) Alterations of the tumor suppressor genes CDKN2A (P16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661–669PubMed

30.

Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183–190PubMed

31.

Lusis EA, Watson MA, Chrcoine MR et al (2005) Integrative genomic analysis identifies NDGR2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningiomas. Cancer Res 65:7121–7126CrossRefPubMed

32.

Bates S, Phillips AC, Clark PA et al (1998) p14ARF links the tumour suppressors RB and p53. Nature 395:124–125CrossRefPubMed

33.

Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ (1996) Radiotherapy for atypical or malignant intracranial meningioma. Int J Radat Oncol Biol Phys 34(4):817–822CrossRef

34.

Dziuk TW, Woo SY, Butler EB, Grossman RG, Goodman C, Harper R, Narayan R, Thornby J, Dennis WS, Hu HL, Carpenter LS, Chiu JK, Munkarah M (1993) Malignant meningioma: an indication for radiotherapy. Int J Radiol Oncol Biol Phys 27(Suppl):264CrossRef

35.

Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW (2010) Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg 113(2):202–209CrossRefPubMed

36.

Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH (2009) Long-term experience with World Health Organization Grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 74(2):427–432PubMed

37.

Boskos C, Feuvret L, Noel G, Habrand J-L, Pommier P, Alapetite C, Mammar H, Ferrand R, Boisserie G, Mazeron J-J (2009) Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys 75(2):399–406PubMed

38.

Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, Lu H, Carpenter LS, Chiu JK (1998) Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 37(2):177–188CrossRefPubMed

39.

Hug EB, DeVries A, Thornton AF, Munzenrider JE, Pardo FS, Hedley-Whyte ET, Bussiere MR, Ojemann R (2000) Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 48:151–160CrossRefPubMed

40.

Mattozo CA, De Salles AA, Klement IA, Gorgulho A, McArthur D, Ford J, Agazaryan N, Kelly DF, Selch MT (2007) Stereotactic radiation treatment for recurrent nonbenign meningiomas. J Neurosurg 106:846–854CrossRefPubMed

41.

Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844CrossRefPubMed

42.

Norden AD, Drappatz J, Wen PY (2007) Targeted drug therapy for meningiomas. Neurosurg Focus 23(4):E12CrossRefPubMed

43.

Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969–973CrossRefPubMed

Title: A review of malignant meningiomas: diagnosis, characteristics, and treatment
Authors: Simon Hanft
Peter Canoll
Jeffrey N. Bruce
Publication date: 01-09-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0348-9

At a glance: The STEP trials

Springer Medicine

A review of malignant meningiomas: diagnosis, characteristics, and treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Surgical navigation for meningioma surgery

Opportunities for clinical research in meningioma

FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients

Aberrant signaling pathways in meningiomas

Meningiomas and neurofibromatosis

Modern meningioma imaging techniques